Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Sign Up to like & getrecommendations! Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2016.06.083
Abstract: Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart… read more here.
Keywords: new class; angiotensin receptor; receptor neprilysin; neprilysin inhibitor ... See more keywords